Press Releases

Date Title and Summary Additional Formats
Toggle Summary Flexion Therapeutics Announces the Retirement of Neil Bodick, M.D., Ph.D., Chief Scientific Officer and Company Co-Founder
BURLINGTON, Mass., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Neil Bodick, M.D., Ph.D., Chief Scientific Officer, will retire effective January 3, 2020 . Dr. Bodick co-founded Flexion in 2007 with Michael Clayman, M.D., the company’s President
View HTML
Toggle Summary Flexion Therapeutics to Host Physician Event at Orthopaedic Summit 2019 Featuring Panel of Former Professional Athletes Treated With ZILRETTA® for Osteoarthritis Knee Pain
NFL broadcaster Solomon Wilcots to go “Knee to Knee” as moderator of discussion with 1980 USA hockey team captain Mike Eruzione, NFL Hall of Fame member Rod Woodson and retired MLB player Chris Dickerson Orthopaedic Summit is the premier gathering of sports medicine and arthroscopic orthopedists
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , Dec. 06, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to six new employees consisting of an aggregate of 25,300 stock options and 4,150 restricted stock units. The Compensation Committee of the Board of Directors
View HTML
Toggle Summary Flexion Therapeutics Presents ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Efficacy Data at the AAHKS and ACR Annual Meetings
Post-hoc sensitivity analysis assessed efficacy in patients who reported moderate-to-severe osteoarthritis (OA) pain prior to treatment on both ADP and WOMAC-A scales In this analysis of concordant pain reporters, ZILRETTA provided durable pain relief that was statistically significant and
View HTML
Toggle Summary Flexion Therapeutics Reports Third-Quarter 2019 Financial Results and Recent Business Highlights
Company reported ZILRETTA ®  (triamcinolone acetonide extended-release injectable suspension) net sales of $21.8 million in Q3 representing 29% growth over Q2 Full-year 2019 ZILRETTA net sales guidance range tightened to $70 million to $75 million Flexion initiated Phase 2 trial investigating
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , Nov. 01, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to four new employees consisting of an aggregate of 14,700 stock options and 2,500 restricted stock units. The Compensation Committee of the Board of Directors
View HTML
Toggle Summary Flexion Therapeutics to Report Third-Quarter 2019 Financial Results on November 7, 2019
BURLINGTON, Mass. , Oct. 31, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its third-quarter 2019 financial results after the close of the U.S. financial markets on Thursday, November 7, 2019 . Flexion’s management will host a conference call
View HTML
Toggle Summary Flexion Therapeutics Announces FDA Clearance of the Investigational New Drug Application for FX201, a Gene Therapy Candidate for the Treatment of Osteoarthritis
In addressing a highly prevalent, non-monogenic musculoskeletal disease, FX201 has the potential to open a new treatment avenue for gene therapy  A single intra-articular injection of FX201 has the potential to both provide long-term symptomatic relief and modify disease progression The Phase 1
View HTML
Toggle Summary Flexion Therapeutics Announces Extended FDA Review of Supplemental New Drug Application for ZILRETTA®
BURLINGTON, Mass. , Oct. 14, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Food and Drug Administration (FDA) has informed the company it needs additional time to complete the review of the supplemental New Drug Application (sNDA) for ZILRETTA
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , Oct. 04, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to 13 new employees consisting of an aggregate of 80,550 stock options and 13,425 restricted stock units. The Compensation Committee of the Board of Directors
View HTML